Business Context and Reporting Period
This Form 6-K filing by Pharming Group N.V. (the "Company") relates to a press release dated February 20, 2025. The filing discloses the outcome of a recommended cash offer made by Pharming Technologies B.V., a wholly-owned subsidiary of the Company, to acquire shares of Abliva AB (publ) ("Abliva"). The offer was initially announced on December 15, 2024, declared unconditional on February 7, 2025, and extended to February 20, 2025.
Key Financial Metrics and Transaction Details
The filing focuses on a specific corporate transaction rather than general operating financials. Key metrics regarding the offer include:
- Offer Price: SEK 0.45 in cash per share.
- Total Shares Controlled: 1,494,181,625 shares.
- Ownership Percentage: Approximately 92.70% of total shares and votes in Abliva.
- Shares Tendered in Initial Period: 1,413,841,472 shares (approx. 87.71%).
- Shares Tendered in Extended Period: 47,327,703 shares (approx. 2.94%).
- Shares Acquired Outside Offer: 33,012,450 shares (approx. 2.05%).
The filing text does not provide clear values for the Company's revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the increase in Pharming's ownership stake in Abliva from approximately 87.71% (at the end of the initial acceptance period) to 92.70% following the extended acceptance period and open market purchases. This acquisition enables Pharming to initiate a compulsory acquisition procedure for the remaining shares under the Swedish Companies Act and delist Abliva from Nasdaq Stockholm.
Outlook, Management Commentary, and Risks
Outlook and Next Steps:
- Pharming has extended the acceptance period for the Offer until March 6, 2025, at 15:00 CET.
- Settlement for shares tendered during this extended period is expected to commence on or around March 12, 2025.
- Pharming intends to initiate a compulsory acquisition procedure for the remaining shares and delist Abliva from Nasdaq Stockholm.
Risks and Contingencies:
- Forward-Looking Statements: The press release contains forward-looking statements regarding future performance and the benefits of the Offer, which involve risks and uncertainties.
- Legal Jurisdiction: The Offer is subject to Swedish law, which may differ from U.S. securities laws. U.S. shareholders may face difficulties enforcing rights in non-U.S. courts.
- Currency Risk: The offer price is in SEK, and no adjustments will be made for exchange rate fluctuations.
- Tax Implications: Acceptance of the Offer may be a taxable transaction for U.S. federal and state income tax purposes.
Important Facts for Investor Verification
- Verify the final settlement date and process for the extended offer period (expected around March 12, 2025).
- Confirm the timeline and regulatory requirements for the compulsory acquisition procedure and delisting of Abliva from Nasdaq Stockholm.
- Assess the tax implications of the cash offer for shareholders in their specific jurisdictions, particularly for U.S. holders.
- Review the offer document at www.raredisease-offer.com for detailed terms and conditions.
- Note that the filing does not contain updated financial statements for Pharming Group N.V. for the period ending February 2025.